* If you want to update the article please login/register
To determine the response rate associated with pazopanib as 3rd-line therapy in metastatic renal cell carcinoma patients who have failed to respond to chemotherapy with a specific vascular endothelial growth factor, a tyrosine kinase inhibitor. To determine if pre-metastatic niche density in regional lymph nodes is related to PFS, it is necessary to determine if PFS is related to PFS. PFS can be used to determine whether phosphorylated signal transducer and transcription 3 modulator of transcription 3 are involved with tumor tissue. Using time to tumor progression on pazopanib as 3rd-line therapy, it will be easy to compare, within patient, time to tumor progression of 2nd-line therapy with time to tumor progression on pazopanib. OUTLINE: Patients receive oral pazopanib hydrochloride every day from days 1-28.
Source link: https://clinicaltrials.gov/ct2/show/NCT01157091
Objectives: To determine the suitability of the Am mindfulness app in metastatic renal cell carcinoma patients with respect to accrual, adherence, and involvement in the project.
Source link: https://clinicaltrials.gov/ct2/show/NCT04788095
Primary Objective: - To determine the safety of intermittent nivolumab therapy in patients with metastatic renal cell carcinoma, follow the following links: - To determine the toxicity of intermittent nivolumab therapy. Secondary Intentions: To determine the clinical outcome in metastatic renal cell carcinoma patients treated with intermittent nivolumab therapy. To determine the risk of intermittent nivolumab therapy in patients with metastatic renal cell carcinoma, we need to investigate the toxicity of intermittent nivolumab therapy.
Source link: https://clinicaltrials.gov/ct2/show/NCT03126331
This is a multi-centre, open label, phase II randomized clinical trial evaluating SBRT as upfront cytoreductive therapy to the primary renal mass, as well as combination I/N therapy in patients with intermediate/poor risk mRCC who are not candidates for cytoreductive nephrectomy. Both induction I/N and SBRT patients based on IMDC criteria with primary disease in-situ will be randomized in a 2:1 fashion to either induction I/N followed by SBRT before the second cycle versus I/N alone. Induction ipilimumab 1 mg/kg infected with nivolumab 3 mg/kg every 3 weeks for cycles 1-4, then maintenance treatment with nivolumab 240 mg every 4 weeks until disease progression, intolerance, or patient/physician decision to stop medication. Induction ipilimumab 1 mg/kg as well as nivolumab 3 mg/kg every three weeks for one cycle, followed by SBRT to the primary disease in-situ, ahead of cycle 2-4 of I/N. Patients randomized to SBRT will be randomized to radiation therapy during the first cycle of I/N to their primary kidney mass, and then the radiation will be administered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day for over 1. 5 weeks. Patients will begin to receive medication with nivolumab 240 mg every two weeks or 480 mg every four weeks until disease progression, intolerance, or patient/physician decision to stop treatment after completion of up to four cycles of I/N.
Source link: https://clinicaltrials.gov/ct2/show/NCT04090710
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions